Covalon Technologies has received approval from the therapeutic product directorate at Health Canada to begin marketing the corporation's proprietary products, Biostep collagen matrix dressing, and Biostep Ag collagen matrix dressing with silver.

Covalon Technologies, an advanced medical biosystems company, has received a notice of allowance for a Canadian patent for drug delivery via therapeutic hydrogels.

Covalon Technologies has achieved an important milestone with its EPAS1 technology that is expected to allow Covalon to engineer mesenchymal stem cells for increased expression of EPAS1, a hypoxia inducible factor.